Targeting the Right Ventricle in Pulmonary Hypertension
Status:
Completed
Trial end date:
2018-01-01
Target enrollment:
Participant gender:
Summary
This study is looking to see if giving ranolazine to subjects on stable pulmonary
hypertension specific therapies but with right ventricular dysfunction (RVEF <45%) would
improve their outcome. This study is accompanied by a baseline comparison of the metabolic
profiling/microRNA/iPS cells of subjects with and without right ventricular dysfunction.
Phase:
Phase 4
Details
Lead Sponsor:
University of Pennsylvania
Collaborators:
Brigham and Women's Hospital The Cardiovascular Medical Research and Education Fund University of Maryland University of Maryland, College Park Washington University School of Medicine Yale University